Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.

Leverett CA, Sukuru SC, Vetelino BC, Musto S, Parris K, Pandit J, Loganzo F, Varghese AH, Bai G, Liu B, Liu D, Hudson S, Doppalapudi VR, Stock J, O'Donnell CJ, Subramanyam C.

ACS Med Chem Lett. 2016 Aug 26;7(11):999-1004. eCollection 2016 Nov 10.

2.

Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.

Tumey LN, Leverett CA, Vetelino B, Li F, Rago B, Han X, Loganzo F, Musto S, Bai G, Sukuru SC, Graziani EI, Puthenveetil S, Casavant J, Ratnayake A, Marquette K, Hudson S, Doppalapudi VR, Stock J, Tchistiakova L, Bessire AJ, Clark T, Lucas J, Hosselet C, O'Donnell CJ, Subramanyam C.

ACS Med Chem Lett. 2016 Jun 22;7(11):977-982. eCollection 2016 Nov 10.

3.

Antitumor efficacy of a thrombospondin 1 mimetic CovX-body.

Li L, Leedom TA, Do J, Huang H, Lai J, Johnson K, Osothprarop TF, Rizzo JD, Doppalapudi VR, Bradshaw CW, Lappe RW, Woodnutt G, Levin NJ, Pirie-Shepherd SR.

Transl Oncol. 2011 Aug;4(4):249-57. Epub 2011 Aug 1.

4.

Intravitreal concentrations of a near-infrared fluorescence-labeled biotherapeutic determined in situ using confocal scanning laser ophthalmoscopy.

Basile AS, Glazier G, Lee A, Jiang LY, Johnson TR, Shields MJ, Vezina M, Doppalapudi VR.

Invest Ophthalmol Vis Sci. 2011 Sep 1;52(9):6949-58. doi: 10.1167/iovs.11-7790.

PMID:
21791590
5.

Evolution of potent and stable placental-growth-factor-1-targeting CovX-bodies from phage display peptide discovery.

Bower KE, Lam SN, Oates BD, Del Rosario JR, Corner E, Osothprarop TF, Kinhikar AG, Hoye JA, Preston RR, Murphy RE, Campbell LA, Huang H, Jimenez J, Cao X, Chen G, Ainekulu ZW, Datt AB, Levin NJ, Doppalapudi VR, Pirie-Shepherd SR, Bradshaw C, Woodnutt G, Lappe RW.

J Med Chem. 2011 Mar 10;54(5):1256-65. doi: 10.1021/jm101226k. Epub 2011 Jan 31.

PMID:
21280651
6.

Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.

Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, Doppalapudi VR, Pirie-Shepherd S, Levin N, Bradshaw C, Woodnutt G, Lappe R, Bhat A.

Clin Cancer Res. 2011 Mar 1;17(5):1001-11. doi: 10.1158/1078-0432.CCR-10-2317. Epub 2011 Jan 13.

7.

Chemical generation of bispecific antibodies.

Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, Desharnais J, Hagen C, Levin NJ, Shields MJ, Parish M, Murphy RE, Del Rosario J, Oates BD, Lai JY, Matin MJ, Ainekulu Z, Bhat A, Bradshaw CW, Woodnutt G, Lerner RA, Lappe RW.

Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22611-6. doi: 10.1073/pnas.1016478108. Epub 2010 Dec 13.

8.

Penicillin sulfone inhibitors of class D beta-lactamases.

Drawz SM, Bethel CR, Doppalapudi VR, Sheri A, Pagadala SR, Hujer AM, Skalweit MJ, Anderson VE, Chen SG, Buynak JD, Bonomo RA.

Antimicrob Agents Chemother. 2010 Apr;54(4):1414-24. doi: 10.1128/AAC.00743-09. Epub 2010 Jan 19.

9.

Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies.

Doppalapudi VR, Tryder N, Li L, Aja T, Griffith D, Liao FF, Roxas G, Ramprasad MP, Bradshaw C, Barbas CF 3rd.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):501-6. Epub 2006 Oct 7.

PMID:
17055724
10.

Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by beta-lactamases.

Stone GW, Zhang Q, Castillo R, Doppalapudi VR, Bueno AR, Lee JY, Li Q, Sergeeva M, Khambatta G, Georgopapadakou NH.

Antimicrob Agents Chemother. 2004 Feb;48(2):477-83.

11.

Cephalosporin-derived inhibitors of beta-lactamase. Part 4: The C3 substituent.

Buynak JD, Vogeti L, Doppalapudi VR, Solomon GM, Chen H.

Bioorg Med Chem Lett. 2002 Jun 17;12(12):1663-6.

PMID:
12039585
12.

NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against beta-lactamase-producing strains.

Li Q, Lee JY, Castillo R, Hixon MS, Pujol C, Doppalapudi VR, Shepard HM, Wahl GM, Lobl TJ, Chan MF.

Antimicrob Agents Chemother. 2002 May;46(5):1262-8.

13.

Inhibition of class C beta-lactamases: structure of a reaction intermediate with a cephem sulfone.

Crichlow GV, Nukaga M, Doppalapudi VR, Buynak JD, Knox JR.

Biochemistry. 2001 May 29;40(21):6233-9.

PMID:
11371184
14.

The synthesis and evaluation of 3-substituted-7-(alkylidene)cephalosporin sulfones as beta-lactamase inhibitors.

Buynak JD, Doppalapudi VR, Adam G.

Bioorg Med Chem Lett. 2000 May 1;10(9):853-7.

PMID:
10853646
15.

The synthesis and evaluation of 2-substituted-7-(alkylidene)cephalosporin sulfones as beta-lactamase inhibitors.

Buynak JD, Doppalapudi VR, Rao AS, Nidamarthy SD, Adam G.

Bioorg Med Chem Lett. 2000 May 1;10(9):847-51.

PMID:
10853645
16.

The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.

Buynak JD, Rao AS, Doppalapudi VR, Adam G, Petersen PJ, Nidamarthy SD.

Bioorg Med Chem Lett. 1999 Jul 19;9(14):1997-2002.

PMID:
10450969

Supplemental Content

Loading ...
Support Center